Key Sessions

Simone Mori

Globalization to Deliver Comprehensive Early Clinical Data to Mitigate the Current Biotech Investment Benchmarks

Moderna

Luba Greenwood

The CVC Perspective: Strategic Venturing in Biotech Throughout 2024 & Beyond

Dana-Farber Cancer Institute

Maha Radhakrishnan

Revolutionizing the Future: Unveiling the Dynamics of Biotech Investment and Deals in the USA

Sofinnova Investments

Michelle Li

Pharma Fusion: Spearheading Growth Through M&A and Partnering in 2024

Bristol Myers Squibb

Tadaaki Taniguchi

Pharma Keynote: Pioneering Partnerships: Building Alliances that Push the Boundaries of Science in Underserved Diseases

Astellas Pharma

Hong Chen

The Pill-ar of Success: Navigating Pharma Collaborations and Spotting Innovation

Novo Nordisk

Day 1 – Wednesday, 11 SEPTEMBERWednesday, 11 September 2024 - ET (Eastern Time, GMT-05:00)

Showing 1 of 1 Streams

BIOTECH LEADERS MORNING KEYNOTE PLENARY : ROOM 312

9:00am - 9:05am

LSX Welcome Address

Adam Griffiths - Senior Director, Biotech Lead, Informa

9:05am - 9:30am

Assessing Biotech Investment Trends in 2024 and Beyond

Cody Powers - Partner, ZS Associates

9:30am - 10:10am

Revolutionizing the Future: Unveiling the Dynamics of Biotech Investment and Deals in the USA

Maha Radhakrishnan - Executive Partner, Sofinnova Investments
Chris Jeffers - SVP, Life Sciences, Brown Rudnick
Jim MacKrell - VP Lilly Venture Science, Eli Lilly
Issi Rozen - General Partner, Google Ventures
Richard Kivel - CEO, Graybella Capital
Bibhash Mukhopadhyay - Managing Partner & Co-Founder, Sound Bioventures

10:10am - 10:30am

Pharma Keynote: Pioneering Partnerships: Building Alliances that Push the Boundaries of Science in Underserved Diseases

Tadaaki Taniguchi - Chief Medical Officer, Astellas Pharma
Christina Corridon - Managing Principal, ZS

10:30am - 11:00am

Morning Break

Showing 3 of 3 Streams

CAPITAL MARKETS & INVESTMENT : ROOM 312

PARTNERSHIPS & DEAL MAKING : ROOM 311

SCALING & COMMERCIALISATION : ROOM 310

11:00am - 11:40am

The Venture Investor Outlook and Investing in the Therapies of Tomorrow

Jeff Quillen - Partner, Foley Hoag
Dirk Landgraf - Partner, SV Health Investors
Evan Caplan - Principal, OrbiMed
Eric Snyder - Partner, Venture Investments, Novo Holdings
Rebecca Luse - Principal, Deep Track Capital
Ralf Saykiewicz - Managing Partner, Raudi Capital

11:40am - 12:00pm

Globalization to Deliver Comprehensive Early Clinical Data to Mitigate the Current Biotech Investment Benchmarks

Simone Mori - Head, External Research Venture, Moderna
Chris Hickey - CBO, Nucleus Networks
Kiran Reddy - Senior Managing Director, Blackstone LIfe Sciences
Biljana Georgievska - CCO, Nucleus Networks

12:00pm - 12:40pm

Understanding Shifts in Early-Stage VC Investment Criteria

Lynn Lewis - Founder & CEO, Gilmartin Group
Stephen Bruso - Partner, Morningside Advisory
John Boyce - Managing Director & Co-Founder, TigerGene
Reetika Bhardwaj - Senior Associate, ARCH Venture Partners

11:00am - 11:40am

The Pill-ar of Success: Navigating Pharma Collaborations and Spotting Innovation

Hong Chen - Director, Search & Evaluation USA, Novo Nordisk
Hannah England - Partner, Ropes & Gray
Mankit Law - Director - BD, Search & Evaluation, GSK
Jeremy O’Hanlon - Executive Director, Global BD, Daiichi-Sankyo
Greg Fralish - CBO, GlycoEra

11:40am - 12:00pm

Partnering Globally: Enabling Different Strategies and Approaches to Drive Innovation

Andrew Whittle - Director, BD&L, Boehringer Ingelheim

12:00pm - 12:40pm

Driving Innovation in Life Sciences Through Fostering Strong Partnerships Between Industry, Academia, and NPOs

Alison Fenney - Executive Director, Strategic Partnerships and Business Operations, Regeneron Genetics Center
Alfred Slanetz - Chairman, National Foundation for Cancer Research
James Zanewicz - Chief Strategy Officer, Tulane University
Peter Meinke - Sanders Director, Tri-Institutional Therapeutics Discovery Institute
Jukka Muhonen - President, AllianceXConsulting

11:00am - 11:40am

Funding Biotech Innovation and Scaling Up

Kyle DiLella - Team Lead, Emerging Corporate Life Sciences, Citibank
Ellen Donnelly - CEO, Abliva
Ann Belien - CEO & Founder, Rejuvenate Biomed
Daniel Janse - CEO, AffyImmune
Dan Passeri - CEO, Cue Biopharma
Rachel Ravens - CEO, 42Genetics

11:40am - 12:00pm

Accelerating Cures: Speeding Up Clinical Trials to Maximize Returns For All

Ben van der Schaaf - Partner, Arthur D. Little
Ben Enejo - Partner, Arthur D. Little

12:00pm - 12:40pm

Integrating CMC Development for Value Creation in Biotech Start-Ups

Zeid Barakat - Partner, Scimitar
Johannes Roebers - Head of Business Development Unit, ProductLife Group
Dan Jacobs - VP, CMC Operations, Flagship Pioneering
Chase Orsello - Global Head Bioprocess Development, Sanofi
Neera Jain - Vice President, Chemical Pharmaceutical Development & Operations, Syros Pharmaceuticals
Federico Pollano - SVP, Business Development, Rentschler

Showing 3 of 3 Streams

CAPITAL MARKETS & INVESTMENT : ROOM 312

PARTNERSHIPS & DEAL MAKING : ROOM 311

SCALING & COMMERCIALISATION : ROOM 310

1:40pm - 2:30pm

Building Strong Biotech Foundations: Governance, Growth, and Fundraising Strategies

Doug Locke - CEO, SSI Strategy
Madhav Gurijala - SVP Business Consulting, SSI Strategy
Steve Zelenkofske - Executive Advisor, SLZ Consulting
Björn Cochlovius - CEO, eleva

2:30pm - 3:20pm

The CVC Perspective: Strategic Venturing in Biotech Throughout 2024 & Beyond

Luba Greenwood - Managing Partner, Binney Street Capital Venture Fund, Dana-Farber Cancer Institute
Marian Nakada - VP, Venture Investments, JJDC
Aaron Nelson - Managing Director, Novartis Venture Fund
Fei Shen - Managing Director, Boehringer Ingelheim Venture Fund
Irena Melnikova - Partner, Pfizer Ventures

1:40pm - 2:30pm

The Oncology Odyssey: Exploring New Market Trends In Cancer Research and Partnering

Alex Philippidis - Senior Business Editor, Genetic Engineering & Biotechnology News
Natalia Ulyanova - Business Development Director, Oncology, Astellas, USA
William Ho - President & CEO, IN8bio
Elizabeth Wood - Founder & CEO, JURA Bio
José Mejía Oneto - CEO, Shasqi
Tim Sullivan - CBO, Infinimmune

2:30pm - 3:20pm

Key Stakeholders in Building a Robust Women’s Health Ecosystem

Anula Jayasuriya - Co-Founder, Kidron Capital
Elizabeth Garner - President, KNI Health Consultants
Elizabeth Bailey - Managing Director, RH Capital
Lori Frank - President, WHAM
Allison Watkins - Founder & CEO, Watkins-Conti Products, Inc
Gerardo Toledo - CEO & Co-founder, Solarea Bio

1:40pm - 2:30pm

Commercialization Strategies for Biotechs and Early-Planning

Joe Goldberg - Partner, RSM US LLP
Dan Oliver - CEO, Rejuvenate Bio
Michelle Chen - CBO, Insilico Medicine
Jeff Landau - CBO, CytomX
Sohail Zaidi - CEO, Ananda Scientific

2:30pm - 3:20pm

Developing an Effective Message and Strategic Positioning in a Crowded Market

David Brower - CBO, Accent Therapeutics
Jae Won Kim - COO & CFO, VantAI
Kimberly Ha - Founder & CEO, KKH Advisors
Michael Goldberg - CEO, Surge Therapeutics
Regina Salvat - Principal, Sofinnova Investments

Showing 1 of 1 Streams

BIOTECH LEADERS AFTERNOON KEYNOTE PLENARY : ROOM 312

3:50pm - 4:30pm

Maximizing Returns: Unleashing the Power of AI for Tangible ROI

Mark Stead - Head of BD, Atomic AI
Greg Ryslik - CTO, COMPASS Pathways
Elizabeth Schwarzbach - CBO, BigHat Biosciences
Ben Hohn - Principal, BD, Pipeline and Launch Strategy, ZS Associates
Kfir Schreiber - CO-founder & CEO, DeepCure

4:30pm - 4:50pm

Forging Alliances and Leveraging Acquisitions to Generate Shared Value for Patients, People, Communities, the Planet and Thriving as Business

Stefano Cottignoli - Head of Global Business and Corporate Development, Chiesi Group

4:50pm - 5:00pm

Biopharma Partnering Benchmarking Report

Michael Rai - General Manager, partneringONE
Millie Nelson - Editor, BioXconomy, Informa Connect Life Sciences

5:00pm - 5:40pm

Pharma Fusion: Spearheading Growth Through M&A and Partnering in 2024

Michelle Li - Vice President and Head, BD&L Transactions, Bristol Myers Squibb
Nicole Daley - Partner, A&O Shearman
Philippe Lopes-Fernandes - EVP, CBO, Ipsen
Dave Moore - EVP, Coporate Development, Novo Nordisk
Sarah Kilpatrick - VP Business Development, Pfizer
Issei Tsukamoto - SVP, Global Head Business Development, Astellas

Day 1 – Wednesday, 11 SEPTEMBERWednesday, 11 September 2024 - ET (Eastern Time, GMT-05:00)

Day 1 – Wednesday, 11 SEPTEMBERWednesday, 11 September 2024 - ET (Eastern Time, GMT-05:00)

Get the Latest Event Updates